BLU

SC 13G - BELLUS Health Inc. (0001259942) (Subject)

SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

15-12G - BELLUS Health Inc. (0001259942) (Filer)

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as patents for some of the industry's blockbuster drugs are on the expiration cliff. The pharmaceutical industry is experiencing strong interest in M&A due to anticipated revenue erosion of approximately $200 billion by the end of the decade. The latest examples include Astellas Pharma Inc (OTC:ALPMY) acquiring American firm Iveric Bio Inc (NASDAQ:ISEE) for $5.9 billion, Pfizer Inc (NYSE:PFE) proposing a $43 billion acquisition of Seagen Inc (NASDAQ:SGEN), GSK plc (NYSE:GSK) agreeing to acquire BELL

S-8 POS - BELLUS Health Inc. (0001259942) (Filer)

S-8 POS - BELLUS Health Inc. (0001259942) (Filer)

6-K - BELLUS Health Inc. (0001259942) (Filer)

6-K - BELLUS Health Inc. (0001259942) (Filer)

LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

6-K - BELLUS Health Inc. (0001259942) (Filer)

BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced the positive outcome of the BELLUS shareholders ("Shareholders") vote at this morning's special meeting of the Shareholders (the "Special Meeting") held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a corporation existing under the laws of Canada and a wholly-owned subsidiary of GSK plc (NYSE:GSK, LSE: GSK))) ("GSK"), will acquire, for a purchase price of US$14.75 in cash per share, all of the issued and outstanding common shares of BELLUS (the

6-K - BELLUS Health Inc. (0001259942) (Filer)

6-K - BELLUS Health Inc. (0001259942) (Filer)

6-K - BELLUS Health Inc. (0001259942) (Filer)

6-K - BELLUS Health Inc. (0001259942) (Filer)

Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a co

RBC Capital analyst Gregory Renza reiterates BELLUS Health (NASDAQ:BLU) with a Sector Perform and maintains $14.75 price target.

BELLUS Health (NASDAQ:BLU) reported its Q1 earnings results on Friday, May 12, 2023 at 04:00 PM. Here's what investors need to know about the announcement. Earnings BELLUS Health missed estimated earnings by 11.11%, reporting an EPS of $-0.2 versus an estimate of $-0.18. Revenue was down $1 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.04 which was followed by a 0.65% increase in the share price the next day. Listen to the earnings announcement yourself by clicking here. To track all earnings releases for BELLUS Health visit their earnings calendar here. This article was generated by Benzinga's automated content engine and r

6-K - BELLUS Health Inc. (0001259942) (Filer)

BELLUS Health (NASDAQ:BLU) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $3.00 thousand in sales this quarter. This is a 25.00 percent decrease over sales of $4.00 thousand the same period last year.

6-K - BELLUS Health Inc. (0001259942) (Filer)

- Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%; transaction expected to close in Q3 2023 – BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the quarter ended March 31, 2023. "Our merger agreement with GSK underscores our corporate and clini

6-K - BELLUS Health Inc. (0001259942) (Filer)

6-K - BELLUS Health Inc. (0001259942) (Filer)

6-K - BELLUS Health Inc. (0001259942) (Filer)